Jenny V Tobin, Daniel P Zimmer, Courtney Shea, Peter Germano, Sylvie G Bernier, Guang Liu, Kim Long, Joy Miyashiro, Sheila Ranganath, Sarah Jacobson, Kim Tang, G-Yoon Jamie Im, James Sheppeck, Joel D Moore, Kristine Sykes, James Wakefield, Renee Sarno, Ali R Banijamali, Albert T Profy, G Todd Milne, Mark G Currie, Jaime L Masferrer
Soluble guanylate cyclase (sGC), a key signal-transduction enzyme, increases the conversion of guanosine-5'-triphosphate (GTP) to cyclic guanosine-3',5'-monophosphate (cGMP) upon binding of nitric oxide (NO). Endothelial dysfunction and/or reduced NO signaling have been implicated in cardiovascular disease pathogenesis and complications of diabetes, and have been associated with other disease states and aging. sGC stimulators are small-molecule drugs that bind sGC and enhance NO-mediated cGMP signaling. The pharmacological characterization of IW-1973, a novel clinical-stage sGC stimulator, is described...
April 11, 2018: Journal of Pharmacology and Experimental Therapeutics